At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Fulvestrantdrug
Likely dose
Fulvestrant 500 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma
Masonic Cancer Center, University of Minnesota·interventional·Posted Feb 15, 2008·Updated Dec 28, 2017
In Brief
A Phase 2 clinical trial evaluating Fulvestrant for Ovarian Cancer. Completed, enrolled 26 participants across 1 site.
Detailed Summary
RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent ovarian epithelial cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedFeb 2008
Primary CompletionApr 2008
Study CompletionJul 2008
TodayJul 2026
First PostedFeb 15, 2008
Enrollment StartJun 1, 2007
Primary CompletionApr 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.4 years ago
Interventions
Fulvestrantdrug
Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.